KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Outstanding (Diluted Average) (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $218.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 5.75% year-over-year to $218.6 million, compared with a TTM value of $218.6 million through Dec 2025, up 5.75%, and an annual FY2025 reading of $218.6 million, up 5.75% over the prior year.
  • Shares Outstanding (Diluted Average) was $218.6 million for Q4 2025 at Biocryst Pharmaceuticals, down from $219.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $219.9 million in Q3 2025 and bottomed at $192.2 million in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 3 years is $209.9 million, with a median of $206.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Diluted Average) increased 7.54% in 2024, then rose 4.46% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $192.2 million in 2023, then rose by 7.54% to $206.7 million in 2024, then grew by 5.75% to $218.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BCRX at $218.6 million in Q4 2025, $219.9 million in Q3 2025, and $217.6 million in Q2 2025.